Brazil halts trials of Chinese COVID-19 vaccine
The Brazilian regulator, Anvisa, said in a statement it had “ruled to interrupt the clinical trial of the CoronaVac vaccine after a serious adverse incident” on October 29.
It said it could not give details on what happened because of privacy regulations, but that such incidents included death, potentially fatal side effects, serious disability, hospitalization, birth defects and other “clinically significant events.”
However, the public health center coordinating the trials of the vaccine in Brazil, the Butantan Institute, said it was “surprised” by the decision.
The institute “is investigating in detail what happened,” and “is at the Brazilian regulatory agency’s disposal to provide any clarification necessary on any adverse incident the clinical trials may have presented,” it said.
It said it would hold a press conference on Tuesday at 11:00 am (1400 GMT).
CoronaVac has been caught up in a messy political battle in Brazil, where its most visible backer has been Sao Paulo Governor Joao Doria, a top opponent of far-right President Jair Bolsonaro.
– Pandemic politics –
Bolsonaro has labeled CoronaVac the vaccine from “that other country,” and pushed instead for a rival vaccine developed by Oxford University and pharmaceutical firm AstraZeneca.
Last month, Bolsonaro shot down a plan by his own health minister to buy 46 million doses of CoronaVac, saying, “The Brazilian people will not be anyone’s guinea pig” and referring to it as “Joao Doria’s Chinese vaccine.”